Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

Therapeutic Potential of Anthracene Derivatives for Breast Cancer

Version 1 : Received: 10 October 2023 / Approved: 10 October 2023 / Online: 11 October 2023 (04:46:44 CEST)

A peer-reviewed article of this Preprint also exists.

Okon, E.; Gaweł-Bęben, K.; Jarzab, A.; Koch, W.; Kukula-Koch, W.; Wawruszak, A. Therapeutic Potential of 1,8-Dihydroanthraquinone Derivatives for Breast Cancer. Int. J. Mol. Sci. 2023, 24, 15789. Okon, E.; Gaweł-Bęben, K.; Jarzab, A.; Koch, W.; Kukula-Koch, W.; Wawruszak, A. Therapeutic Potential of 1,8-Dihydroanthraquinone Derivatives for Breast Cancer. Int. J. Mol. Sci. 2023, 24, 15789.

Abstract

Breast cancer (BC) is the most common malignancy among women worldwide. In recent years, significant progress has been made in BC therapy. However, serious side effects resulting from the use of standard chemotherapeutic drugs, as well as the phenomenon of multidrug resistance (MDR), limit the effectiveness of approved therapies. Advanced research in the BC area is necessary to create more effective and safer forms of therapy to improve the outlook for individuals diagnosed with this aggressive neoplasm. For decades, plants and natural products with anti-cancer properties have been successfully utilized in treating various medical conditions. Anthracene derivatives are tricyclic secondary metabolites of natural origin that have been identified in plants, lichens, and fungi. They represent a few botanical families, e.g., Rhamnaceae, Rubia-ceae, Fabaceae, Polygonaceae, and others. The review comprehensively covers and analyzes the most recent advances in the anticancer activity of anthracene derivatives (emodin, aloe-emodin, hypericin, chrysophanol, rhein, and physcion) applied both individually, or in combination with other chemotherapeutic agents in in vitro and in vivo BC models.

Keywords

anthracene derivatives; breast cancer; natural products; biological activity; emodin; aloe-emodin; hypericin; chrysophanol; rhein; physcion

Subject

Medicine and Pharmacology, Oncology and Oncogenics

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.